Cell therapy is a fast-growing and highly promising field in the development of novel therapeutics, with a strong potential to provide innovative functional cures.


While most current cell therapies focus on autologous therapies, off-the-shelf allogenic approaches based on induced pluripotent stem cells (iPSC) offer significant advantages compared to both autologous and donor-derived allogenic therapies.  


It is Evotec’s goal to provide safe, efficacious and cost-effective cell therapy products to large patient groups across a broad range of disease areas. To achieve that, Evotec has built a unique, industry-leading end-to-end platform to develop and manufacture off-the-shelf iPSC-based cell therapeutics, fully integrated under one roof. In addition, we conduct R&D to develop innovative proprietary product candidates to accelerate pipeline building with our partners.

Advantages of iPSC-based Approach

iPSC based cell therapy
  • Reduced complexity: Patient is not part of manufacturing process
  • Unlimited starting material
  • Clonal & high fidelity gene editing
  • Consistent quality of final product
  • On demand product availability to patients
  • Versatile: Single platform suitable to manufacture multiple cell types & diseases

A Truly Off-The-Shelf, Scalable Approach

Our approach is fully scalable to serve the market with up to tens of thousands of doses. Thus, we overcome a major hurdle a major hurdle in cell therapy.

iPSC Large Scale GMP Manufacturing To Clinic
TODO

iPSC Cell Therapy Platform Overview

Learn more about our iPSC-based cell therapy platform.

Learn more

Flexible Partnership & Collaboration Models

Evotec’s internal iPSC-based product candidate pipeline is one of the broadest in the industry. It encompasses immunotherapies for cancer and autoimmune diseases, as well as regenerative therapies targeting diabetes and heart failure. Additionally, the platform integrates cutting-edge gene editing and targeting technologies, along with a GMP facility for manufacturing clinical development candidates.

In line with Evotec’s mission “Together for Medicines that Matter”, we are seeking strategic partners to collaborate and co-develop a product candidate pipeline in multiple diseases areas. Our collaboration and partnership models are flexible and tailored to our partners’ needs.

Partnering model i PSC CT 230811

Meet Our Expert

Headshot Andreas Scheel
Evotec logo big

Andreas Scheel, PhD

EVP, Head of Cell Therapy

Evotec logo big

Latest update: November 2025

Biography


Andreas Scheel, as the EVP Head of Cell Therapy, leads the focus area “iPSC-based Cell Therapies” at Evotec. He also serves as the site head of the Cologne facility and is responsible for the cell therapy core teams located in Göttingen and Cologne.


In his role, Andreas is primarily responsible for the strategic development of this focus area together with a leadership team and for the establishment of strategic partnerships. He ensures the teams have the required expertise and fosters a cohesive identity across different sites. Andreas actively engages in internal networking and garners management support to promote transparency as this field continues to grow within the company. Additionally, he provides vital support to specific projects.


Andreas and his team's work holds immense importance, as they develop novel therapies to address urgent patient needs, striving to cure (rather than just treat) specific diseases with the unique advantages of iPSC-based cell therapy. At Evotec, Andreas values the company's commitment to investing in promising areas, granting senior leaders like himself the autonomy to define strategies. The dynamic and diverse environment at Evotec, with its vast expertise and multicultural teams, allows Andreas to excel in developing innovative platforms that have the potential to revolutionize medical treatments. His dedication and leadership position him as an invaluable asset in Evotec's pursuit of groundbreaking therapies.


Interest and Experience


Apart from his professional achievements, Andreas finds joy and fulfillment in his family and sports. He thrives in fast-paced environments and embraces challenging situations, making critical decisions with urgency, which allows him to tap into his creativity and excel in his work at Evotec.

Evotec logo big
TODO

Integrated Solutions for Cell Therapy IND and Beyond

Learn more about our cell therapy development and manufacturing capabilities.

Learn more
Andreas Scheel

Andreas Scheel, PhD

EVP, Head of Cell Therapy

vCard
Logo Evotec white
Evotec has the right technologies & disease understanding to meet our partners' evolving needs: a comprehensive disease knowledge at the molecular level, cutting-edge technologies & platforms to translate this expertise into effective precision medicines.